zithromax and Anemia--Sickle-Cell

To this day, there are limited data about the effects and management of coronavirus disease infection in pediatric patients with sickle cell disease. We present the management and successful clinical course of an 8-year-old female with homozygous sickle cell disease (SS) and severe acute chest syndrome secondary to coronavirus disease 2019 infection, complicated by cortical vein thrombosis.

Topics: Anemia, Sickle Cell; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Child; COVID-19; Erythrocyte Transfusion; Female; Humans; Intensive Care Units; Systemic Inflammatory Response Syndrome

As the COVID-19 pandemic continues to claim lives across the globe, insufficient data exists regarding the optimal treatment. It is well known that patients 55 years of age or older and patients with certain chronic diseases are at higher risk of severe illness, including acute respiratory distress syndrome and death. A potentially fatal pulmonary complication of sickle cell disease, acute chest syndrome, can be precipitated by acute infections, including respiratory viruses. We report the case of a patient with sickle cell disease (HbSC) who developed COVID-19 pneumonia and acute chest syndrome who was treated with emergent red blood cell exchange in order to avoid endotracheal intubation.

Topics: Acute Chest Syndrome; Adult; Analgesics; Anemia, Sickle Cell; Antiviral Agents; Azithromycin; Betacoronavirus; Combined Modality Therapy; Contraindications, Procedure; Coronavirus Infections; COVID-19; Erythrocyte Transfusion; Humans; Hydroxychloroquine; Intubation, Intratracheal; Male; Methylprednisolone; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Respiration, Artificial; Respiratory Insufficiency; SARS-CoV-2